Alternative Data for Tarsus Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 34 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 28,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 137 | Sign up | Sign up | Sign up |
| Facebook Followers | 634 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,292 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 913 | Sign up | Sign up | Sign up |
| X Followers | 645 | Sign up | Sign up | Sign up |
| X Mentions | 26 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 386 | Sign up | Sign up | Sign up |
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States.
| Price | $67.96 |
| Target Price | Sign up |
| Volume | 476,041 |
| Market Cap | $2.89B |
| Year Range | $38.82 - $82.51 |
| Dividend Yield | 0% |
| Analyst Rating | 86% buy |
| Industry | Biotechnology |
In the news
Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform RatingMarch 6 - Yahoo Entertainment |
|
Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster PotentialFebruary 23 - SeekingAlpha |
|
Tarsus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 sales results.February 23 - Benzinga |
|
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call TranscriptFebruary 23 - SeekingAlpha |
|
 |
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Q4 2025 Earnings: Revenue Soars on XDEMVY Sales, But Losses WidenFebruary 23 - ChartMill |
Tarsus Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call PresentationFebruary 23 - SeekingAlpha |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 119M | 25M | 94M | -13M | -12M | -0.300 |
| Q2 '25 | 103M | 6.2M | 96M | -20M | -18M | -0.480 |
| Q1 '25 | 78M | 5.2M | 73M | -25M | -22M | -0.640 |
| Q4 '24 | 66M | 4.9M | 61M | -23M | -20M | -0.600 |
| Q3 '24 | 48M | 3.2M | 45M | -23M | -21M | -0.610 |
Insider Transactions View All
| Neervannan Seshadri filed to sell 70,817 shares at $76.7. March 5 '26 |
| Whitfield Dianne C. filed to sell 24,286 shares at $81.9. January 6 '26 |
| Whitfield Dianne C. filed to sell 23,393 shares at $82.9. January 6 '26 |
| Whitfield Dianne C. filed to sell 33,243 shares at $80.1. January 6 '26 |
| Whitfield Dianne C. filed to sell 25,121 shares at $80.7. January 6 '26 |
Similar companies
Read more about Tarsus Pharmaceuticals (TARS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Tarsus Pharmaceuticals
The Market Cap of Tarsus Pharmaceuticals is $2.89B.
Currently, the price of one share of Tarsus Pharmaceuticals stock is $67.96.
The TARS stock price chart above provides a comprehensive visual representation of Tarsus Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tarsus Pharmaceuticals shares. Our platform offers an up-to-date TARS stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Tarsus Pharmaceuticals (TARS) does not offer dividends to its shareholders. Investors interested in Tarsus Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Tarsus Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
